-transparent.png){kind=logo}
A controlled clinical trial of the anti-inflammatory, analgesic, muscle-relaxing and anxiolytic activity of a new compound (parsalmide) was compared with that of phenybutazone in 40 patients with acute or exacerbated inflammatory or degenerative processes randomly distributed into two treatment groups. Parsalmide was more effective in the relief of joint swelling and anxiety and gave better motility. On an overall evaluation, however, it was on a par with phenylbutazone. Treatment had to be suspended in two cases treated with phenylbutasone, whereas tolerance was good with parsalmide and no suspensions were required.
Related Publications
G Tafner, and
M Pedrazzoli, and
E Bajocchi
February 1976,
Bollettino chimico farmaceutico,
G Tafner, and
M Pedrazzoli, and
E Bajocchi
October 1976,
Minerva medica,
G Tafner, and
M Pedrazzoli, and
E Bajocchi
October 1976,
Minerva medica,
G Tafner, and
M Pedrazzoli, and
E Bajocchi
January 1973,
Therapie,
G Tafner, and
M Pedrazzoli, and
E Bajocchi
October 1976,
Minerva medica,
G Tafner, and
M Pedrazzoli, and
E Bajocchi
April 1967,
Minerva medica,
G Tafner, and
M Pedrazzoli, and
E Bajocchi
December 1977,
La Clinica terapeutica,
G Tafner, and
M Pedrazzoli, and
E Bajocchi
May 1989,
La Clinica terapeutica,
G Tafner, and
M Pedrazzoli, and
E Bajocchi
October 1976,
Minerva medica,
G Tafner, and
M Pedrazzoli, and
E Bajocchi
January 1977,
Minerva urologica,
